Premium
IC–P–085: MR–guided 3D PET mapping of longitudinal changes in regional cerebral metabolism of normal subjects
Author(s) -
Apostolova Liana G.,
Dinov Ivo D.,
Thompson Paul M.,
Zoumalan Charleen,
Steiner Calen A.,
Siu Erin,
Dutton Rebecca A.,
Hayashi Kiralee M.,
Small Gary W.,
Cummings Jeffrey L.,
Toga Arthur W.,
Phelps Michael E.,
Silverman Daniel H.S.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.2290
Subject(s) - precuneus , posterior cingulate , magnetic resonance imaging , positron emission tomography , medicine , nuclear medicine , cardiology , radiology , functional magnetic resonance imaging
tion. Methods: Ten drug naı̈ve, non-smoking, AD patients (78 12 years) underwent cognitive assessment and a static 20-min PET scan 100min after injection of 200MBq 2-[F]F-A-85380 on two separate occasions (before and after 8-weeks,16mg/d galantamine treatment). Brain regional binding was assessed through a simplified estimation of Distribution Volume (DVS), defined as the region to metabolite corrected venous plasma ratio at apparent steady state (100-120min post-injection). Correlational analysis was conducted to investigate the possible relationship between changes in DVS and cognition following galantamine treatment. Results: Treatment was well tolerated and only two patients experienced minor side effects at the 16mg/d galantamine dose. AD patients showed enhanced performance on global measures of cognition after galantamine treatment, reflected in an improvement in MMSE and AD Assessment Scale (ADAS-Cog) performance (10% and 35%, respectively). This improvement was also reflected in tasks measuring verbal fluency, verbal recall, and psychomotor function. On the repeat 2-[F]F-A-85380 PET scans a small increase (6.3%) was observed in DVS, probably reflecting an increase in nAChRs binding sites. A trend level relationship was observed between changes in DVS and cognitive performance. Conclusions: [F]F-A-85380 PET allows the evaluation of drug effects at the specific site of pharmacological action. There is some evidence to suggest that the observed improvements on specific measures of cognition might be related to the up-regulation of nAChRs as measured by [F]F-A-85380 and PET after the 8-week galantamine treatment regime.